Edward-L Krawitt

Summary

Affiliation: University of Vermont
Country: USA

Publications

  1. doi Discrimination of autoimmune hepatitis: autoantibody typing and beyond
    Edward L Krawitt
    Department of Medicine, University of Vermont, Given Building, Burlington, VT 05405 0068, USA
    J Gastroenterol 46:39-41. 2011
  2. pmc Clinical features and management of autoimmune hepatitis
    Edward L Krawitt
    Department of Medicine, University of Vermont, Given C 246 Burlington, Vermont 05405 0068, USA
    World J Gastroenterol 14:3301-5. 2008
  3. ncbi Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C
    Edward L Krawitt
    Department of Medicine, University of Vermont, Burlington, VT, USA
    J Hepatol 43:243-9. 2005
  4. ncbi Autoimmune hepatitis
    Edward L Krawitt
    Department of Medicine, University of Vermont, Burlington, VT 05405 0068, USA
    N Engl J Med 354:54-66. 2006
  5. ncbi A study of low dose peginterferon alpha-2b with ribavirin for the initial treatment of chronic hepatitis C
    Edward L Krawitt
    Department of Medicine, University of Vermont, Burlington, Vermont, and Department of Medicine, Brigham and Women s Hospital, Boston, MA, USA
    Am J Gastroenterol 101:1268-73. 2006
  6. pmc Differences in hepatic phenotype between hemochromatosis patients with HFE C282Y homozygosity and other HFE genotypes
    Raymond Cheng
    Department of Medicine, University of Washington, Seattle, WA, USA
    J Clin Gastroenterol 43:569-73. 2009
  7. pmc Variability of grade and stage in simultaneous paired liver biopsies in patients with hepatitis C
    Silvia Skripenova
    Department of Pathology, University of Vermont College of Medicine, Burlington, Vermont, USA
    J Clin Pathol 60:321-4. 2007
  8. ncbi Continued treatment of chronic hepatitis C despite development of interferon-associated retinopathy
    Mark A Cedar
    Am J Gastroenterol 102:2612-3. 2007
  9. ncbi Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis
    Elizabeth D Morrison
    University of Washington, Seattle, Washington 98195, USA
    Ann Intern Med 138:627-33. 2003
  10. ncbi Heterozygous alpha1-antitrypsin deficiency and chronic hepatitis C
    Daniel S Pratt
    Gastrointestinal Unit, Massachusetts General Hospital, Boston, Massachusetts, USA
    Clin Gastroenterol Hepatol 3:xxix. 2005

Collaborators

Detail Information

Publications14

  1. doi Discrimination of autoimmune hepatitis: autoantibody typing and beyond
    Edward L Krawitt
    Department of Medicine, University of Vermont, Given Building, Burlington, VT 05405 0068, USA
    J Gastroenterol 46:39-41. 2011
    ..Whether or not IgG4-associated autoimmune hepatitis is a distinct entity awaits a more extensive description of clinical and immuno-histological features...
  2. pmc Clinical features and management of autoimmune hepatitis
    Edward L Krawitt
    Department of Medicine, University of Vermont, Given C 246 Burlington, Vermont 05405 0068, USA
    World J Gastroenterol 14:3301-5. 2008
    ..Liver transplantation is generally successful in patients with decompensated cirrhosis unresponsive to or intolerant of medical therapy...
  3. ncbi Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C
    Edward L Krawitt
    Department of Medicine, University of Vermont, Burlington, VT, USA
    J Hepatol 43:243-9. 2005
    ..However, little is known about the utility of such regimens for individuals who failed to respond to prior conventional interferon-based treatment...
  4. ncbi Autoimmune hepatitis
    Edward L Krawitt
    Department of Medicine, University of Vermont, Burlington, VT 05405 0068, USA
    N Engl J Med 354:54-66. 2006
  5. ncbi A study of low dose peginterferon alpha-2b with ribavirin for the initial treatment of chronic hepatitis C
    Edward L Krawitt
    Department of Medicine, University of Vermont, Burlington, Vermont, and Department of Medicine, Brigham and Women s Hospital, Boston, MA, USA
    Am J Gastroenterol 101:1268-73. 2006
    ..By nature of its design the study also provided data on response to therapy over a spectrum of doses of both pegylated interferon alpha-2b and ribavirin calculated on a body weight basis...
  6. pmc Differences in hepatic phenotype between hemochromatosis patients with HFE C282Y homozygosity and other HFE genotypes
    Raymond Cheng
    Department of Medicine, University of Washington, Seattle, WA, USA
    J Clin Gastroenterol 43:569-73. 2009
    ..The goal of this study was to compare hepatic histopathologic features and hepatic iron concentration (HIC) among patients with phenotypic hemochromatosis and different HFE genotypes...
  7. pmc Variability of grade and stage in simultaneous paired liver biopsies in patients with hepatitis C
    Silvia Skripenova
    Department of Pathology, University of Vermont College of Medicine, Burlington, Vermont, USA
    J Clin Pathol 60:321-4. 2007
    ..Spatial disease variability relative to markers of the adequacy of biopsy has not been studied previously...
  8. ncbi Continued treatment of chronic hepatitis C despite development of interferon-associated retinopathy
    Mark A Cedar
    Am J Gastroenterol 102:2612-3. 2007
  9. ncbi Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis
    Elizabeth D Morrison
    University of Washington, Seattle, Washington 98195, USA
    Ann Intern Med 138:627-33. 2003
    ..DNA-based HFE gene testing can confirm hereditary hemochromatosis in most people of Northern European descent. However, liver biopsy is important to detect cirrhosis...
  10. ncbi Heterozygous alpha1-antitrypsin deficiency and chronic hepatitis C
    Daniel S Pratt
    Gastrointestinal Unit, Massachusetts General Hospital, Boston, Massachusetts, USA
    Clin Gastroenterol Hepatol 3:xxix. 2005
  11. ncbi Treatment challenges and investigational opportunities in autoimmune hepatitis
    Albert J Czaja
    Mayo Clinic College of Medicine, Division of Gastroenterology and Hepatology, Rochester, MN 55905, USA
    Hepatology 41:207-15. 2005
    ..In conclusion, evolving pharmacological and technical advances promise to improve the treatment of autoimmune hepatitis, and investigations of these advances are timely, feasible, and necessary...
  12. ncbi Sampling variability in liver biopsies
    Edward L Krawitt
    J Hepatol 41:886-7. 2004
  13. doi Simplified criteria for the diagnosis of autoimmune hepatitis
    Elke M Hennes
    Department of Medicine, University Medical Centre Hamburg Eppendorf, Germany
    Hepatology 48:169-76. 2008
    ..CONCLUSION: A reliable diagnosis of AIH can be made using a very simple diagnostic score. We propose the diagnosis of probable AIH at a cutoff point greater than 6 points and definite AIH 7 points or higher...
  14. ncbi Gastrointestinal bleeding, cryoglobulinemia, and hepatitis C
    Gregg D Fine
    Am J Gastroenterol 99:964-5. 2004